Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies
New therapies will allow patients greater choice and flexibility in the control of CNS disorders
Barcelona, Spain / Düsseldorf, Germany and Athens, Greece – 12 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in Greece and leaders in the development and supply of long-acting injectable (LAI) therapies, announce a strategic alliance to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.
